尼达尼布对具有快速进展危险因素的系统性硬化症相关间质性肺病患者的作用
SENSCIS 试验纳入高分辨率 CT 显示纤维化间质性肺病范围≥10%的系统性硬化症患者,分析 52 周内用力肺活量(FVC)下降速率;安慰剂组中,病程<18 个月、炎症标志物升高或皮肤纤维化范围大的患者 FVC 下降数值上更快,尼达尼布在各亚组均降低 FVC 下降速率,且在这些危险因素患者中效应数值上更大。
要点
- 安慰剂组中,病程<18 个月者 FVC 下降-167.8 mL/年,高于总体人群的-93.3 mL/年。
- 炎症标志物升高者安慰剂组 FVC 下降-100.7 mL/年,mRSS≥18 者为-131.7 mL/年。
- 尼达尼布在各亚组均降低 FVC 下降速率,危险因素患者中效应数值上更大。
核心结论
- 在 SENSCIS 试验中,具有早期系统性硬化症、炎症标志物升高或广泛皮肤纤维化的系统性硬化症相关间质性肺病患者,52 周内 FVC 下降比总体试验人群更快。
- 尼达尼布在这些间质性肺病快速进展危险因素患者中的效应数值上更大。
研究设计与样本
- SENSCIS 试验纳入系统性硬化症且高分辨率 CT 显示纤维化间质性肺病范围≥10%的受试者。
- 分析全部受试者及具有早期系统性硬化症(首次非雷诺现象症状出现<18 个月)、炎症标志物升高(C 反应蛋白≥6 mg/L 和/或血小板≥330×10⁹/L)或显著皮肤纤维化(改良 Rodnan 皮肤评分 15-40 或≥18)者 52 周内 FVC 下降速率。
主要发现
- 安慰剂组 FVC 下降速率:总体人群-93.3 mL/年,首次非雷诺现象症状出现<18 个月者-167.8 mL/年,炎症标志物升高者-100.7 mL/年,mRSS 15-40 者-121.7 mL/年,mRSS≥18 者-131.7 mL/年。
- 尼达尼布降低了各亚组的 FVC 下降速率,在上述快速 FVC 下降危险因素患者中效应数值上更大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC. METHODS: The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of ≥10% extent on high-resolution CT. The rate of decline in FVC over 52 weeks was analysed in all subjects and in those with early SSc (<18 months since first non-Raynaud symptom), elevated inflammatory markers (C reactive protein ≥6 mg/L and/or platelets ≥330×109/L) or significant skin fibrosis (modified Rodnan skin score (mRSS) 15-40 or mRSS ≥18) at baseline. RESULTS: In the placebo group, the rate of decline in FVC was numerically greater in subjects with <18 months since first non-Raynaud symptom (-167.8 mL/year), elevated inflammatory markers (-100.7 mL/year), mRSS 15-40 (-121.7 mL/year) or mRSS ≥18 (-131.7 mL/year) than in all subjects (-93.3 mL/year). Nintedanib reduced the rate of FVC decline across subgroups, with a numerically greater effect in patients with these risk factors for rapid FVC decline. CONCLUSION: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.
引用
- Khanna D, Maher TM, Volkmann ER, et al. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open. 2023. PMID: 36796874. doi:10.1136/rmdopen-2022-002859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。